Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week High on Analyst Upgrade

Spyre Therapeutics, Inc. (NASDAQ:SYRE)’s stock price reached a new 52-week high during mid-day trading on Monday after Robert W. Baird raised their price target on the stock from $65.00 to $90.00. Robert W. Baird currently has an outperform rating on the stock. Spyre Therapeutics traded as high as $75.00 and last traded at $65.3690, with a volume of 1256982 shares. The stock had previously closed at $51.29.

SYRE has been the subject of a number of other reports. Citigroup assumed coverage on Spyre Therapeutics in a research report on Wednesday, December 17th. They set a “buy” rating and a $64.00 target price for the company. Wedbush increased their target price on Spyre Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday. Stifel Nicolaus increased their target price on Spyre Therapeutics from $70.00 to $92.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Leerink Partners increased their target price on Spyre Therapeutics from $49.00 to $106.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Raymond James Financial assumed coverage on Spyre Therapeutics in a research report on Monday. They set a “strong-buy” rating and a $80.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $82.50.

Insider Activity

In related news, CEO Cameron Turtle sold 15,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $49.33, for a total value of $739,950.00. Following the completion of the sale, the chief executive officer directly owned 627,540 shares in the company, valued at $30,956,548.20. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sheldon Sloan sold 7,958 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $50.00, for a total value of $397,900.00. Following the completion of the sale, the insider owned 7,958 shares of the company’s stock, valued at approximately $397,900. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 62,958 shares of company stock worth $2,734,375. 6.20% of the stock is currently owned by insiders.

Spyre Therapeutics News Roundup

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Top-line SPY001 Part A (SKYLINE) Phase 2 induction data show rapid, deep efficacy and a clean safety profile — 9.2‑point RHI reduction, ~40% clinical remission and ~51% endoscopic improvement at 12 weeks, claims best‑in‑class potential. Reuters: Spyre’s inflammatory bowel drug shown to reduce disease activity in mid-stage study
• Positive Sentiment: Company press release highlights statistically significant primary endpoint and frames SPY001 as “potential best‑in‑class,” underpinning upside for commercial and combination-regimen value. GlobeNewswire: SPY001 Part A Induction Results
• Positive Sentiment: Multiple sell‑side firms raised targets and ratings after the data: Leerink to $106 (Outperform), BTIG to $98 (Buy), and Robert W. Baird to $90 (Outperform) — these upgrades increase upside expectations and buy‑side interest. Benzinga: Analyst Price Target Raises
• Positive Sentiment: Analyst/market commentary (Seeking Alpha) frames the SPY001 dataset as a catalyst-rich setup for 2026 with valuation implying high expectations for mono and combination uses. Seeking Alpha: Strong SPY001 Data
• Neutral Sentiment: Trading was briefly halted early on the news (“news pending”), a common step around material corporate/clinical announcements; the halt has ended and normal trading resumed. Trading Halt Notice
• Negative Sentiment: Spyre launched an underwritten public offering to raise $300M of common stock (with a 30‑day option for an additional $45M), which creates near‑term dilution risk and may pressure the share price. GlobeNewswire: Proposed Public Offering
• Negative Sentiment: Market reaction was mixed: coverage notes an immediate sell‑off tied to the offering announcement, reflecting investor sensitivity to dilution despite the strong clinical readout. Investing.com: Stock Falls on $300M Offering

Institutional Trading of Spyre Therapeutics

Institutional investors have recently bought and sold shares of the stock. Persistent Asset Partners Ltd bought a new stake in Spyre Therapeutics in the fourth quarter worth $74,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Spyre Therapeutics by 61.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company’s stock worth $124,000 after buying an additional 1,435 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Spyre Therapeutics by 2,881.7% in the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock worth $71,000 after buying an additional 4,092 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Spyre Therapeutics by 182.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock worth $86,000 after buying an additional 3,725 shares during the last quarter. Finally, Martingale Asset Management L P bought a new stake in Spyre Therapeutics in the fourth quarter worth $227,000. 80.39% of the stock is currently owned by institutional investors.

Spyre Therapeutics Price Performance

The company has a market capitalization of $5.04 billion, a P/E ratio of -30.77 and a beta of 2.93. The business has a 50-day moving average of $43.04 and a 200-day moving average of $33.08.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). Sell-side analysts predict that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.